# ULTRAGENYX PHARMACEUTICAL INC. (RARE) · Edgar & Edgarette company card

> Ultragenyx Pharmaceutical (RARE) grew revenue 20.2% in FY2025 to $673 million, operating margin -79.5% against a -3.8% median for pharmaceutical preparations, equity -5.2% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1515673 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/RARE) · [JSON](https://www.pops4.com/boards/company/RARE.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $673M |
| Revenue growth, 1 year | 20.2% |
| Revenue growth per year | 17.6% |
| Operating margin | -79.5% (prior year -95.7%) |
| Net margin | -85.4% |
| Operating cash flow | −$466M |
| Capital spending | $6M |
| Free cash flow | −$472M |
| Cash | $421M |
| Long-term debt | — |
| Total assets | $1.5B |
| Total equity | −$80M |
| Equity ÷ assets | -5.2% |
| Return on equity | — |
| Dividend per share | $0 |
| Dividend years rising | 0 |

## Readings, computed from those figures

- Altman Z: -9.61 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed restructuring or exit costs in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -79.5% in FY2025
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $673.0M (FY2025). Experience: revenue up 20.2% on the year, up 17.6% a year over 4 years; operating margin -79.5%, up from -95.7%. Soundness: equity -5.2% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $683.0M and $940.8M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $629.9M to $1.0B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -79.5% against a -3.8% median; growth 20.2% against 13.7%.

Range logged 2026-09-29, receipt 01bfa4e2dc54ce91, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 2.05 Restructuring or exit costs: 2, latest 2026-11-03 ([filing](https://www.sec.gov/Archives/edgar/data/1515673/000119312526445342/0001193125-26-445342-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-05-18 ([filing](https://www.sec.gov/Archives/edgar/data/1515673/000119312526228639/0001193125-26-228639-index.htm))

## Recent filings

- 10-Q · filed 2026-11-04 · [filing](https://www.sec.gov/Archives/edgar/data/1515673/000119312526445718/0001193125-26-445718-index.htm)
- 8-K · filed 2026-11-03 · 2.01 Completion of Acquisition or Disposition of Assets; 2.02 Results of Operations and Financial Condition; 2.05 Costs Associated with Exit or Disposal Activities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1515673/000119312526445342/0001193125-26-445342-index.htm)
- 8-K · filed 2026-10-19 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1515673/000119312526424739/0001193125-26-424739-index.htm)
- 8-K · filed 2026-10-14 · 1.01 Entry into a Material Definitive Agreement · [filing](https://www.sec.gov/Archives/edgar/data/1515673/000119312526421079/0001193125-26-421079-index.htm)
- 8-K · filed 2026-10-07 · 1.01 Entry into a Material Definitive Agreement · [filing](https://www.sec.gov/Archives/edgar/data/1515673/000119312526416251/0001193125-26-416251-index.htm)
- 8-K · filed 2026-09-17 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1515673/000151567326000006/0001515673-26-000006-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001515673.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1515673

## Cite

POPS4, Edgar & Edgarette: ULTRAGENYX PHARMACEUTICAL INC. (RARE) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/RARE. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.